Theravance Biopharma (TBPH) Long-Term Deferred Tax (2014 - 2024)

Theravance Biopharma (TBPH) has 5 years of Long-Term Deferred Tax data on file, last reported at $2.4 million in Q4 2024.

• Long-Term Deferred Tax for Q4 2024 came in at $2.4 million, down 99.46% year-over-year; the trailing twelve-month figure through Dec 2024 was $2.4 million (down 99.46% YoY), and the FY2024 annual result was $2.4 million, down 99.46% from the prior year.
• Long-Term Deferred Tax retreated to $2.4 million in Q4 2024 per TBPH's latest filing, from $447.3 million in the prior quarter.
• Over five years, Long-Term Deferred Tax peaked at $447.3 million in Q4 2023 and troughed at $2.4 million in Q4 2024.
• A 3-year average of $296.8 million and a median of $440.7 million in 2022 frame the typical range for Long-Term Deferred Tax.
• The sharpest annual moves came in 2023 and 2024: Long-Term Deferred Tax advanced 1.49% in 2023, then tumbled 99.46% in 2024.
• A 3-year view of Long-Term Deferred Tax shows it stood at $440.7 million in 2022, then gained by 1.49% to $447.3 million in 2023, then plunged by 99.46% to $2.4 million in 2024.
• Business Quant data shows TBPH's Long-Term Deferred Tax at $2.4 million in Q4 2024, $447.3 million in Q4 2023, and $440.7 million in Q4 2022.